Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

For patients already receiving metformin therapy, the starting dose should be based on the patient's current metformin regimen. The total daily dose should not exceed 100 mg sitagliptin and 2000 mg metformin.

Metformin and sitagliptin are known to be substantially excreted by the kidney. The risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus, patients with serum creatinine levels above the upper limit of normal for their age should not receive JANUMET. In the elderly, JANUMET should be carefully titrated to establish the minimum dose for adequate glycemic effect, because aging can be associated with reduced renal function. Any dose adjustment should be based on a careful assessment of renal function. Before initiation of therapy with JANUMET and at least annually thereafter, renal function should be assessed and verified as normal.

Selected cautionary information for JANUVIA

Because JANUVIA is renally eliminated, and to achieve plasma concentrations of JANUVIA similar to those in patients with normal renal function, a dosage adjustment is recommended in patients with moderate renal insufficiency and in patients with severe renal insufficiency or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis. Safety and effectiveness of JANUVIA in pediatric patients have not been established. There are no adequate and well-controlled studies in pregnant women. JANUVIA should be used during pregnancy only if clearly needed. Caution should be exercised when JANUVIA is administered to a nursing woman. In clinical trials, JANUVIA demonstrated an overall incidence of side effects comparable to placebo. The most common side effects reported with JANUVIA (greater than or equal to 5 percent and higher than placebo) were stuffy or runny nose and sore throat, upper respiratory infection, and headache.

Selected cautionary information for JANUMET

JANUMET should b
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:8/28/2015)... , Aug. 28, 2015  With the heroin ... reaching deadlier heights, Jacksonville -based Lakeview ... Hemphill is helping to explain why fentanyl is ... approximately 40 to 50 times more potent than pharmaceutical ... users as heroin, the risk of death skyrockets. ...
(Date:8/28/2015)... SAN FRANCISCO, Calif. , Aug. 28, 2015 /PRNewswire/ ... for the treatment of cancer, today announced the filing ... U.S. Securities and Exchange Commission (SEC) relating to a ... number of shares to be offered and the price ... CytomX intends to list its common stock under the ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Pranoprofen Market, 2010-2019" ... discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly ... inflammatory drug, pranoprofen was later developed into eye ... trade name of pranopulin for the treatment of ...
Breaking Medicine Technology:Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 2
... on Benefit of Intensive Blood Sugar Control Are, Not Statistically Significant but ... ... Events, SAN FRANCISCO, June 8 Findings from ... study in high-risk diabetes patients were,released today at the 68th Scientific Sessions ...
... Therapy in Q1 2008, SAN FRANCISCO, June 7 ... Lilly and Company (NYSE: LLY ) today announced,additional ... diabetes who were,unable to achieve glycemic control through diet ... BYETTA(R) (exenatide),injection taken twice daily or placebo. Study findings ...
Cached Medicine Technology:Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 2Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 3Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 4Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss 2Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss 3Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss 4Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss 5Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss 6Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss 7
(Date:8/31/2015)... ... ... A year ago this month, Seniors Guide first hit stands in the Columbus, ... successful first year. , “We started the magazine with the goal of giving ... says Melissa Wolfert, founding Publisher for Seniors Guide Columbus. “Making the decision to move ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company ... Bright Pink® to raise money and awareness for breast and ovarian health. ... Pink Sassy incandescent Mood-lite sold to Bright Pink® to encourage households, dorms, and ...
(Date:8/31/2015)... ... 31, 2015 , ... It’s a lot like coming home. Life-long Fox Valley ... During his first days on the job, he’s run into residents of the retirement ... like knowing that they’re living in such a wonderful place,” he said. GreenFields, which ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... executive networking and relationship-marketing firm, announced today the nominees vying for the ... Northeast U.S. Region. Executives include top-ranking decision makers representing national to global ...
(Date:8/31/2015)... ... ... According to book reviewer Angie Santangeloon , Dr. Jack Westman 's ... an excellent resource for everyone since one in three persons will have life threatening ... cancer is in a easy to understand medically accurate way. The book builds the ...
Breaking Medicine News(10 mins):Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 2Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 3Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 4Health News:New Book The Cancer Solution Is a Must Read for Everyone Affected by Cancer 2
... By Steven Reinberg HealthDay Reporter , THURSDAY, ... Americans routinely sleep fewer than seven hours a night, ... research shows. Insufficient sleep also impairs work performance ... the U.S. Centers for Disease Control and Prevention (CDC), ...
... 3 (HealthDay News) -- An analysis of breast tissue may ... a new study reports. Researchers analyzed what they describe ... found that the way collagen fibers -- the main component ... patient,s diagnosis and help determine treatment. Collagen not only ...
... pain of neuropathy may affect feet and hands before ... that supply the extremities age and become dysfunctional as ... Hopkins scientists suggest in a new study. The finding ... a condition that often accompanies other diseases including HIV/AIDS, ...
... a common but painful deformity of the foot, are more likely ... found. And the more severe the bunion, the more likely ... body, leading to declines in both general and foot-specific health-related quality ... develops on the side of the big toe as it leans ...
... new report detailing recent global changes in the management ... examines the evolving landscape of HIV and its associated ... available, as well as offering insight into the trends ... is limited. The report appears in the March ...
... findings on how tuberculosis (TB) bacteria develop multi-drug tolerance point ... The study will be published April 1 in the journal ... a potential therapy for drug tolerance that is induced in ... Currently, TB treatment requires a complex, long-term curative regimen of ...
Cached Medicine News:Health News:1 in 3 Americans Gets Less Than 7 Hours of Sleep: CDC 2Health News:1 in 3 Americans Gets Less Than 7 Hours of Sleep: CDC 3Health News:Tissue Analysis May Help Predict Breast Cancer Outcome 2Health News:Feet first? Old mitochondria might be responsible for neuropathy in the extremities 2Health News:Feet first? Old mitochondria might be responsible for neuropathy in the extremities 3Health News:ATS issues report on emerging issues in HIV-associated pulmonary disease 2Health News:ATS issues report on emerging issues in HIV-associated pulmonary disease 3Health News:New findings on drug tolerance in TB suggest ideas for shorter cures 2Health News:New findings on drug tolerance in TB suggest ideas for shorter cures 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: